BioSpace News Archive

Transparency Market Research has published a new report titled, ‘Global Rubber Gloves Market’.

Advancements in science and technology has aided in improving healthcare outcomes. With better diagnostic and treatment techniques at the behest, doctors are able to prevent patients from suffering and improve treatment process, time, and reduce expenditure.

Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alternative to surgical removal of cervical lesions

Yokogawa Electric Corporation and Integrated Commissioning and Qualification Consultants, Corp. of Southborough announce that they have entered into a partnership agreement under which ICQ Consultants will provide consulting and engineering services for the installation, maintenance, qualification, and support of Yokogawa’s bioreactor systems and related products in the United States.

XPhyto Therapeutics Corp., is pleased to announce that it has placed the first order for its rapid point-of-care SARS-CoV-2 RT-PCR test system from its exclusive diagnostic development partner, 3a-diagnostics GmbH.

Core One Labs Inc. a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy is pleased to announce it has entered into a definitive agreement to acquire Ketamine Infusion Centers of Texas Inc., a US based health and wellness Ketamine Clinic.

Enamine Ltd. a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments and screening compounds announced that it has extended its long-standing research collaboration with Addex Therapeutics Ltd, a clinical-stage pharmaceutical company specialized in allosteric modulation-based drug discovery and development.

Dogs with chronic lower back pain could eventually find relief from a treatment that already exists.

Following consultations with US FDA and EU EMA, two pivotal Phase 3 clinical trial designs are finalized to assess 2 mg OPT-302 administered 4-weekly or 8-weekly in combination with Lucentis® (ShORe study) and Eylea® (COAST study) standard of care

Net new business of $872.4 million in the fourth quarter excluding reimbursement revenue; representing growth of 32.4%; Net book-to-bill of 1.42